neutral
6 days agoCORONA Remedies IPO draws attention with strong GMP and branded chronic pharma focus
Investor interest gathered pace around the CORONA Remedies IPO as the issue opened between December 8 and December 10, 2025, at a price band of Rs 1,008 to Rs 1,062 per share. The Rs 655.37 crore offering is entirely an offer for sale, meaning no fresh capital will flow into the business. Grey market premium hovered near Rs 290 to Rs 300, indicating positive listing expectations, though it remains an unofficial indicator. The company earns most of its revenue from chronic therapies such as diabetes, cardiac care, and women’s health, with over 70 percent of domestic sales driven by long term prescriptions.
Indmoney• By Pooja Kumari
Explore:Mutual Fund AI Screening
neutral
6 days agoCORONA Remedies IPO draws attention with strong GMP and branded chronic pharma focus
Investor interest gathered pace around the CORONA Remedies IPO as the issue opened between December 8 and December 10, 2025, at a price band of Rs 1,008 to Rs 1,062 per share. The Rs 655.37 crore offering is entirely an offer for sale, meaning no fresh capital will flow into the business. Grey market premium hovered near Rs 290 to Rs 300, indicating positive listing expectations, though it remains an unofficial indicator. The company earns most of its revenue from chronic therapies such as diabetes, cardiac care, and women’s health, with over 70 percent of domestic sales driven by long term prescriptions.
Indmoney• By Pooja Kumari
Explore:High Return Equity Mutual Fund
1 min read
102 words
Strong grey market sentiment lifted interest in the CORONA Remedies IPO, even as investors weighed its pure offer-for-sale structure, premium valuation, and reliance on chronic therapy segments.
Investor interest gathered pace around the CORONA Remedies IPO as the issue opened between December 8 and December 10, 2025, at a price band of Rs 1,008 to Rs 1,062 per share. The Rs 655.37 crore offering is entirely an offer for sale, meaning no fresh capital will flow into the business. Grey market premium hovered near Rs 290 to Rs 300, indicating positive listing expectations, though it remains an unofficial indicator. The company earns most of its revenue from chronic therapies such as diabetes, cardiac care, and women’s health, with over 70 percent of domestic sales driven by long term prescriptions.
Investor interest gathered pace around the CORONA Remedies IPO as the issue opened between December 8 and December 10, 2025, at a price band of Rs 1,008 to Rs 1,062 per share. The Rs 655.37 crore offering is entirely an offer for sale, meaning no fresh capital will flow into the business. Grey market premium hovered near Rs 290 to Rs 300, indicating positive listing expectations, though it remains an unofficial indicator. The company earns most of its revenue from chronic therapies such as diabetes, cardiac care, and women’s health, with over 70 percent of domestic sales driven by long term prescriptions.
Dec 9, 2025 • 05:45